Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261588 | 0.98 | SLC6A3 (0.40) | SLC6A3ALDH1A1HPGDRAB9ATSHR | |
| Hydrochloric Acid SCHEMBL17818958 | 0.96 | SLC6A3 (0.39) | SLC6A3ALDH1A1HPGDRAB9ATSHR | |
| SCHEMBL23695650 | 0.96 | SLC6A3 (0.38) | SLC6A3ALDH1A1HPGDRAB9ATSHR | |
| SCHEMBL4916608 | 0.92 | ALOX5 (0.36) | SLC6A3RAB9ATSHRKMT2ANPC1 | |
| SCHEMBL23695497 | 0.92 | ALOX5 (0.36) | SLC6A3RAB9ATSHRKMT2ANPC1 | |
| SCHEMBL12261646 | 0.92 | ALOX5 (0.36) | SLC6A3RAB9ATSHRKMT2ANPC1 | |
| SCHEMBL6874522 | 0.77 | MAPT (0.39) | ALDH1A1HPGDRAB9ATSHRMEN1 | |
| SCHEMBL9791528 | 0.76 | MAPT (0.44) | ALDH1A1HPGDRAB9ATSHRMEN1 | |
| SCHEMBL11379881 | 0.76 | MAPT (0.44) | SLC6A3ALDH1A1HPGDRAB9ATSHR | |
| SCHEMBL9555629 | 0.74 | RAB9A (0.36) | SLC6A3ALDH1A1HPGDRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940563-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021147123-A1 | COMPOUND HAVING ANTISPORULANT ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | 成都贝诺科成生物科技有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-7776879-B2 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2010-08-17 | — | — | US | disclosed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL PRODESFARMA AG | 2008-01-24 | — | — | US | disclosed |
| CN-100363363-C | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL PRODESFARMA SA (CH) | 2008-01-23 | — | — | CN | disclosed |
| EP-1345937-B1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2004-12-30 | — | — | US | disclosed |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | LABORATORIOS ALMIRALL S.A. (ES) | 2004-12-02 | — | — | US | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| EP-1345937-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051841-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| EP-0010401-B1 | NOVEL (1-SUBSTITUTED) CYCLOALKYLMETHYL-ISOTHIOCYANATES, A PROCESS FOR THEIR PREPARATION, COMPOSITIONS COMPRISING THEM, AND THEIR USE AS PESTICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-05-05 | — | — | EP | disclosed |
| US-4216217-A | FUNGICIDES, INSECTICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-05 | — | — | US | disclosed |
| EP-0010401-A2 | Novel (1-substituted) cycloalkylmethyl-isothiocyanates, a process for their preparation, compositions comprising them, and their use as pesticides | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | SLC6A3 1197/4885ALDH1A1 1723/4885HPGD 2312/4885 |
| US-20080021060-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | SLC6A3 675/4885ALDH1A1 1193/4885HPGD 4155/4885 |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | SLC6A3 573/4885ALDH1A1 1591/4885HPGD 4085/4885 |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM1, CHRM2 | SLC6A3 622/4885ALDH1A1 1413/4885HPGD 4127/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | SLC6A3 1327/4885ALDH1A1 2119/4885HPGD 2262/4885 |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CASP9, CLPP, CASP1 | SLC6A3 3653/4885ALDH1A1 3037/4885HPGD 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.